Key result
Obesity combined with antiphospholipid syndrome worsens obstetric outcomes, driven by endothelial dysfunction and systemic inflammation.
This review highlights the challenges and complications associated with obesity and antiphospholipid syndrome during pregnancy.
May warrant closer surveillance in obese antiphospholipid syndrome pregnancies; hypothesis-generating for prospective mechanistic and interventional studies.
Obesity is associated with a broad spectrum of chronic diseases, as well as cardiovascular diseases, such as diabetes, dyslipidemia, insulin resistance and hyperglycemia. Obesity during pregnancy is of major concern due to the well-known risk factors for both the mother and the child. Complications in pregnancy include recurrent miscarriages, gestational diabetes, hypertensive disorders, thromboembolism, and stillbirth. Additionally, maternal obesity seems to have long-term consequences for offspring, predisposing or "programming" them to the development of metabolic disease in adulthood. Antiphospholipid syndrome (APS) is an autoimmune disease and is characterized by the presence of antiphospholipid antibodies (anticardiolipin antibodies/ACLA, lupus antikoagulans/LA and 2-glycoprotein) in the maternal circulation. These antibodies are associated with arterial and/or venous thromboses and with adverse obstetric outcomes such as recurrent fetal loss, Preeclampsia (PE), Intrauterine growth restriction (IUGR) and Intrauterine fetal death (IUFD).
No takes yet. Share an insight, caveat, or question.
K Mayer-Pickel (2015) conducted a review in Obesity and Antiphospholipid Syndrome in Pregnancy. Obesity and Antiphospholipid Syndrome was evaluated. The co-occurrence of obesity and antiphospholipid syndrome in pregnancy worsens obstetric outcomes, likely due to shared mechanisms involving endothelial dysfunction and systemic inflammation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: